News

Leveraging data from a pair of commercial databases, a new study details the changes in febuxostat prescribing among patients with gout before, during, and after the FDA's addition of a Boxed Warning to prescribing information.

Pediatric rheumatologists were most likely to postpone the decision to withdraw biologic therapy when the patient and/or parents expressed a preference for continuation.

The campaign was inspired by the findings of a global survey conducted with healthcare providers about organ damage in lupus patients.

A retrospective analysis of nearly 150 patients with gouty arthritis in China provides further insight into the relationship between pathological ultrasound features and clinical signs and symptoms among this patient population.

Women with psoriatic arthritis reported higher mean pain and worse mean patient global assessment when compared with men.

In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.

No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.

At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

The pooled analysis showed the risk of all-cause dementia was decreased in patients with gout, particularly in patients receiving medication.

Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.

An increased hazard ratio was observed for all-cause mortality, including a standardized mortality ratio for accidents and an increased risk for mortality from infections and suicide.

Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.

Improvements in CDAI by >5 points were associated with improvements in the 5 PROMIS domains and increased satisfaction with rheumatoid arthritis treatment.

The rheumatology month in review features studies reporting increased depression rates among patients with autoimmune disease, interventions designed to decrease chronic pain symptoms in fibromyalgia, and highlights from EULAR 2023.

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

Of the randomized controlled trials identified, only 41% involved patients with depression.

Obstructive sleep apnea was linked to an increased risk of gout in the female subgroup.

Most patients with lupus nephritis reported moderate anxiety and moderate depression which impacted their disease activity and quality of life.

Patients with SLE who reported being more satisfied in their lives were more likely to have higher physical and mental component summary scores.

Women with gout were more likely to exhibit chronic kidney disease, heart failure, dementia, diabetes mellites, and obesity, among others, when compared with men.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Among patients with rheumatoid arthritis, fibromyalgia was present in 31% of patients, compared with 4% of controls.

Serum levels of BD-2 at baseline were shown to be significantly linked with subsequent clinical response in patients with psoriatic arthritis.

The predominant themes observed were the presence of a specific trigger (stressful event) for fibromyalgia symptoms, fulfilling expected gender roles, a lack of support from family members, and abuse.

Themes regarding improvement experience, developing strategies for better health, and contextual factors supporting improvement were reported during the interview analysis.

Pain intensity, quality of life, and depression were significantly improved in a cohort of patients with fibromyalgia treated with THC.

The yoga-based, mind-body intervention was effective for most patients with chronic pain, with the largest effects demonstrated in areas of pain self-efficacy, pain intensity, quality of life, and most severe perceived pain.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.